There are 2789 resources available
667P - Cost effectiveness of immune checkpoint inhibitors in combination with targeted therapies in metastatic renal cell carcinoma
Presenter: Neil Mason
Session: ePoster Display
Resources:
Abstract
668P - Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
Presenter: Camillo Guglielmo Porta
Session: ePoster Display
669P - Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Presenter: Rustem Gafanov
Session: ePoster Display
670P - Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
Presenter: Marine Gross-Goupil
Session: ePoster Display
632P - Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)
Presenter: Benedito A Carneiro
Session: ePoster Display
633P - Mutational landscape differences between young-onset and older-onset prostate cancer patients
Presenter: Yong Wang
Session: ePoster Display
635P - Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer
Presenter: Hui-Ming Lin
Session: ePoster Display
636P - A comparative analysis of prostate cancer short-term recurrence risk forecast performance between 8-gene signature and commercial panels
Presenter: Jinan Guo
Session: ePoster Display